UK markets closed

GlobeImmune, Inc. (GBIM)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00000.0000 (0.00%)
At close: 02:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.01M
Enterprise value -6.68M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.32
Price/book (mrq)N/A
Enterprise value/revenue -1.08
Enterprise value/EBITDA 3.44

Trading information

Stock price history

Beta (5Y monthly) -192.37
52-week change 3-71.43%
S&P500 52-week change 322.38%
52-week high 30.0007
52-week low 30.0000
50-day moving average 30.0002
200-day moving average 30.0002

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 55.75M
Implied shares outstanding 610.07B
Float 84.37M
% held by insiders 10.00%
% held by institutions 10.02%
Shares short (15 Jul 2016) 4129.39k
Short ratio (15 Jul 2016) 40.1
Short % of float (15 Jul 2016) 43.49%
Short % of shares outstanding (15 Jul 2016) 42.25%
Shares short (prior month 15 Jun 2016) 4114.55k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2015
Most-recent quarter (mrq)31 Mar 2016

Profitability

Profit margin -33.30%
Operating margin (ttm)-91.46%

Management effectiveness

Return on assets (ttm)-10.25%
Return on equity (ttm)-66.24%

Income statement

Revenue (ttm)6.21M
Revenue per share (ttm)1.08
Quarterly revenue growth (yoy)-20.60%
Gross profit (ttm)N/A
EBITDA -1.94M
Net income avi to common (ttm)-2.07M
Diluted EPS (ttm)-0.0000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.69M
Total cash per share (mrq)1.51
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.28
Book value per share (mrq)0.37

Cash flow statement

Operating cash flow (ttm)-5.9M
Levered free cash flow (ttm)-1.65M